08.28.15
Mayne Pharma is investing $65 million to expand facilities and equipment at its site in Greenville, NC. The plan includes construction of a new, 126,000-sq.-ft., large-scale oral-dose manufacturing facility, along with the repurposing of existing space to expand contract services.
The new facility, when operational in 2018, will more than double Mayne Pharma’s manufacturing capacity in the U.S. The company, which currently employs 350 people in NC, anticipates hiring as many as 110 more scientists, quality assurance specialists, manufacturing operators and technicians to support expanded operations.
“Expanding our Greenville operations solidifies Mayne Pharma’s aspirations in the U.S. market, while building our talented workforce. Once operational, we can take on new and larger products, specifically those that rely upon our company’s drug-delivery and potent handling expertise,” said Stefan Cross, president of Mayne Pharma USA.
Mayne Pharma will construct the new facility on a campus that houses its products business, along with its CDMO business, Metrics Contract Services, which provides contract pharmaceutical development services to third parties globally.
The new facility will allow Mayne Pharma to expand development, manufacturing and packaging operations for generic and specialty drug products, and expand services to Metrics clients with commercial manufacturing requirements. Also, the introduction of commercial-scale manufacturing of modified release and highly potent drug products will support on-market products, as well as a pipeline of products under development.
The new facility, when operational in 2018, will more than double Mayne Pharma’s manufacturing capacity in the U.S. The company, which currently employs 350 people in NC, anticipates hiring as many as 110 more scientists, quality assurance specialists, manufacturing operators and technicians to support expanded operations.
“Expanding our Greenville operations solidifies Mayne Pharma’s aspirations in the U.S. market, while building our talented workforce. Once operational, we can take on new and larger products, specifically those that rely upon our company’s drug-delivery and potent handling expertise,” said Stefan Cross, president of Mayne Pharma USA.
Mayne Pharma will construct the new facility on a campus that houses its products business, along with its CDMO business, Metrics Contract Services, which provides contract pharmaceutical development services to third parties globally.
The new facility will allow Mayne Pharma to expand development, manufacturing and packaging operations for generic and specialty drug products, and expand services to Metrics clients with commercial manufacturing requirements. Also, the introduction of commercial-scale manufacturing of modified release and highly potent drug products will support on-market products, as well as a pipeline of products under development.
